Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial
Posted inCardiology Diabetes & Endocrinology Nephrology news

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite kidney endpoint in a population with preserved baseline renal function.
Nurse-Led Education Program Effectively Reduces Treatment Delay in Patients with Diabetic High-Risk Foot: A Randomized Controlled Trial
Posted inDiabetes & Endocrinology news Nursing & care

Nurse-Led Education Program Effectively Reduces Treatment Delay in Patients with Diabetic High-Risk Foot: A Randomized Controlled Trial

This randomized controlled trial demonstrates that a structured nurse-led education intervention significantly improves foot care knowledge and self-efficacy while reducing both the intention and actual behavior of delaying treatment in patients with diabetic high-risk foot.
Quantitative Retinal Leakage on Ultra-Widefield Imaging: A New Biomarker for Predicting Diabetic Retinopathy Progression
Posted inDiabetes & Endocrinology news Ophthalmology

Quantitative Retinal Leakage on Ultra-Widefield Imaging: A New Biomarker for Predicting Diabetic Retinopathy Progression

A post hoc analysis of the DRCR Retina Network Protocol AA reveals that automated quantitative leakage index on ultra-widefield fluorescein angiography independently predicts the 4-year risk of DRSS worsening and vision-threatening complications in patients with nonproliferative diabetic retinopathy.
Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies
Posted inDiabetes & Endocrinology news Psychiatry

Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies

A massive systematic review of 5.5 million patients reveals that those with mental disorders receive significantly lower quality diabetes care, including less frequent monitoring and a 74% lower likelihood of being prescribed GLP-1 receptor agonists compared to those without psychiatric conditions.
High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status
Posted inDiabetes & Endocrinology Infectious Diseases news Public Health

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patients with diabetes, particularly those with a disease duration exceeding five years.
Six Months of Intermittent Fasting: Potent Lipid Lowering but Limited Impact on Vascular and Glycemic Markers
Posted inCardiology Diabetes & Endocrinology news

Six Months of Intermittent Fasting: Potent Lipid Lowering but Limited Impact on Vascular and Glycemic Markers

A randomized controlled trial investigates the 6-month effects of intermittent fasting on overweight adults, revealing significant improvements in lipid profiles and body composition despite neutral effects on blood pressure and glucose metabolism, alongside novel transcriptomic insights into GLP-1 signaling.
Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes
Posted inDiabetes & Endocrinology news

Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes

A randomized controlled trial demonstrates that a 20g whey protein pre-load 30 minutes before breakfast significantly reduces postprandial glucose excursions and glycemic variability in women with gestational diabetes throughout the third trimester, offering a promising non-pharmacological management strategy.
Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial
Posted inCardiology Diabetes & Endocrinology news

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial

The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of target-lesion failure and revascularization at 12 months.